Evaluation of chitosan NPs loaded with Camellia sinensis (L.) Kuntze extract for targeted therapy against Pseudomonas aeruginosa-associated SKOV3 ovarian cancer cells

The emergence of multidrug-resistant bacteria, such as Pseudomonas aeruginosa, poses significant challenges in treating infections and associated cancers like ovarian cancer.Novel therapeutic strategies that simultaneously address bacterial resistance and cancer progression are urgently needed.This study evaluates the therapeutic efficacy of chitosan nanoparticles (CNPs) loaded with Camellia sinensis extract against Pseudomonas aeruginosa-associated SKOV3 ovarian cancer cells.CNPs were synthesized and characterized for size, morphology, and encapsulation efficiency.Cytotoxicity was evaluated using the MTT assay on SKOV3 cells.The antibacterial activity of the CNPs was assessed through biofilm inhibition and bacterial load reduction assays.Inflammatory and oxidative stress markers, including TNF-, IL-6, MDA, CAT, and SOD, were measured.Apoptosis was confirmed through caspase-3 activity analysis.CNPs loaded with Camellia sinensis extract exhibited optimal physicochemical properties.Cytotoxicity assays demonstrated significant inhibition of SKOV3 cell viability, with low IC50 values.Antibacterial studies revealed enhanced efficacy in reducing biofilm formation and bacterial growth.Treatment significantly reduced inflammatory markers (TNF-, IL-6, MDA) and elevated antioxidant enzymes (CAT, SOD).Apoptosis induction was confirmed by increased caspase-3 activity.The synergistic anticancer and antibacterial effects of the extract loaded CNPs outperformed both extract alone and standard treatments.Extract-loaded CNPs demonstrate potent dual action against Pseudomonas aeruginosa and SKOV3 ovarian cancer cells, positioning them as a promising therapeutic option for combating infection-driven cancers.